Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Associati...( Presentation Details Statistically...),Health

Presentation Details Statistically Significant and Clinically Relevant Results for SB-509 in Development for Treatment of Diabetic Neuropathy

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of encouraging Phase 1b clinical data from its ZFP Therapeutic(TM) program at the 68th Scientific Sessions of the American Diabetes Association (ADA). As disclosed in an oral presentation entitled, "Evidence of Neuroregeneration Using Vascular Endothelial Growth Factor (VEGF) Zinc Finger Protein Activator (SB-509) in Diabetic Neuropathy: A Chronic Degenerative Polyneuropathy," results of Sangamo's Phase 1b clinical trial (SB-509-401) demonstrated statistically significant improvements in measurements of nerve health and function in subjects with diabetic neuropathy.

"We are excited by the clinically relevant magnitude of improvements that were observed in measurements of nerve health and function in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single administration of SB-509," commented the presenter, Mark Kipnes, M.D., lead investigator on the Phase 1 trial and an endocrinologist at the Diabetes and Glandular Disease Clinic, San Antonio, Texas. "Analgesics and antidepressants designed to control pain symptoms are the only drugs currently approved to treat this condition. In contrast, SB-509 is designed to address the actual nerve damage. These data demonstrate that SB-509 may have a neuroprotective and a neuroregenerative effect."

The data presented at ADA were collected from subjects with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 (SB-509-401). Subjects recei
'/>"/>